MHRA Grants Conditional Marketing Authorisation for Tepkinly® ▼ (epcoritamab) as a Bispecific Treatment for Adults with Relapsed or Refractory DLBCL After Two or More Lines of Systemic Therapy

AbbVie (NYSE: ABBV) today announced that the UK Medicines and Healthcare products Regulatory Agency has granted conditional Marketing Authorisation for Tepkinly® ▼ (epcoritamab) as a monotherapy for the treatment of adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), after two or more ...

Related Keywords

United Kingdom ,Nottingham ,Great Britain ,Chris Fox ,Belinda Byrne ,University Of Nottingham ,School Of Medicine ,Regulatory Agency ,Nottingham University Hospitals ,United Kingdom Medicines ,Marketing Authorisation ,Professor Chris Fox ,Honorary Consultant Haematologist ,Medical Director ,Abbvie United ,